Effect of drospirenone-containing combined oral contraceptive pills on anthropometric and sonographic characteristics and carbohydrate metabolism parameters in women with polycystic ovary syndrome

• Main Authors: L.V. Saprykina (Author), M.R. Narimanova (Author), D.M. Ibragimova (Author)
• Format: Book
• Published: LCC «Medicine-Inform», 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

<p> L.V. Saprykina, M.R. Narimanova, D.M. Ibragimova </p> <p> Pirogov Russian National Research Medical University, Moscow, Russian Federation </p> <p> <b>Background: </b>polycystic ovary syndrome (PCOS) is an endocrine disorder affecting 10% of women of reproductive age. Combined oral contraceptive pills (COCP) are effective in PCOS. Drospirenone is a new progestin with properties similar to natural progesterone (including anti-mineralocorticoid and antiandrogenic activities). </p> <p> <b>Aim</b>: to evaluate the effect of drospirenone-containing COCP (20 µg ethinylestradiol and 3 mg drospirenone) on anthropometric and sonographic characteristics, and carbohydrate metabolism parameters in women with PCOS. </p> <p> <b>Patients and Methods:</b> this prospective study enrolled 22 women of reproductive age (mean age 22.1±0.5 years) with PCOS. All females were treated during six cycles (28 days each). At baseline and 6 months after starting treatment, anthropometric (body mass index/BMI, waist-to-hip ratio/WHR) and sonographic (ovary volume) characteristics, and carbohydrate metabolism parameters (plasma insulin, fasting glucose, homeostasis model assessment of insulin resistance/HOMA-IR) were assessed. </p> <p> <b>Results</b>: 6 months after starting treatment, a significant (p<0.05) reduction in BMI (from 22.54±0.43 kg/m² to 20.86±0.26 kg/m²), WHR (from 0.81±0.01 to 0.78±0.01), and ovary volume (left ovary: from 12.75±0.43 cm³ to 8.05±0.15 cm³; right ovary: from 13.0±0.54 cm³ to 8.63±0.14 cm³) was reported. Meanwhile, no significant (р>0.05) changes in plasma insulin concentration (9.91±0.42 µU/ml vs. 9.52±0.31 µU/ml), fasting blood glucose (4.95±0.08 mmol/l vs. 4.9±0.07 mmol/l), and HOMA-IR (3.2±1.12 vs. 3.06±0.07) compared to baseline levels were reported. The most common side effects were headache or dizziness (n=3, 13.6%), nausea (n=2, 9.1%) and irregular bleeding (n=3, 13.6%). </p> <p> <b>Conclusion: </b>drospirenone-containing COCP has a beneficial effect on anthropometric paramaters and ovary volume but does not affect <b>c</b>arbohydrate metabolism. This drug is characterized by excellent compliance. </p> <p> <b>Keywords: p</b>olycystic ovary syndrome, drospirenone, body mass index, waist-hip ratio, reproductive age, ovary volume, glucose, insulin, carbohydrates, HOMA-IR. </p> <p> <b>For citation:</b> Saprykina L.V., Narimanova M.R., Ibragimova D.M. Effect of drospirenone-containing combined oral contraceptive pills on anthropometric and sonographic characteristics and carbohydrate metabolism parameters in women with polycystic ovary syndrome. Russian Journal of Woman and Child Health. 2022;5(2):118-121 (in Russ.). DOI: 10.32364/2618-8430-2022-5-2-118-121. </p> <br>

Item Description

2618-8430
2686-7184